GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US-China Biomedical Technology Inc (GREY:UCBB) » Definitions » Revenue

US-China Biomedical Technology (US-China Biomedical Technology) Revenue : $0.00 Mil (TTM As of May. 2019)


View and export this data going back to 2011. Start your Free Trial

What is US-China Biomedical Technology Revenue?

US-China Biomedical Technology's revenue for the three months ended in May. 2019 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in May. 2019 was $0.00 Mil. US-China Biomedical Technology's Revenue per Share for the three months ended in May. 2019 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in May. 2019 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


US-China Biomedical Technology Revenue Historical Data

The historical data trend for US-China Biomedical Technology's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US-China Biomedical Technology Revenue Chart

US-China Biomedical Technology Annual Data
Trend Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19
Revenue
Get a 7-Day Free Trial - - - - -

US-China Biomedical Technology Quarterly Data
Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of US-China Biomedical Technology's Revenue

For the Health Information Services subindustry, US-China Biomedical Technology's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US-China Biomedical Technology's Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, US-China Biomedical Technology's Revenue distribution charts can be found below:

* The bar in red indicates where US-China Biomedical Technology's Revenue falls into.



US-China Biomedical Technology Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in May. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


US-China Biomedical Technology  (GREY:UCBB) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


US-China Biomedical Technology Revenue Related Terms

Thank you for viewing the detailed overview of US-China Biomedical Technology's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


US-China Biomedical Technology (US-China Biomedical Technology) Business Description

Traded in Other Exchanges
N/A
Address
2 Park Plaza, Suite 400, Irvine, CA, USA, 92614
US-China Biomedical Technology Inc is an early stage biomedical technology and services company. It is engaged in the integration and development of synergistic relationships with high profiled doctors and hospitals that will act as a bridge for connecting patients and bio-technology advances in China with its network of US based doctors and hospitals. It provides services for moving patients from China to the US with an emphasis on the demographics including pre-screening and genetic testing for family members of cancer patients, patients suffering from Diabetes, and general medical services including preventative care and physicals.

US-China Biomedical Technology (US-China Biomedical Technology) Headlines

No Headlines